Summary

Andrew Mammen, M.D., Ph.D., joined NIAMS as Muscle Disease Unit Leader in the Laboratory of Muscle Stem Cells and Gene Regulation in 2014. He obtained his medical degree and Ph.D. in neuroscience at Johns Hopkins in 2000, where he subsequently completed his medicine internship, neurology residency, and neuromuscular fellowship. Prior to his appointment at NIH, he was Associate Professor of Neurology and Medicine at the Johns Hopkins University School of Medicine. He co-founded the Johns Hopkins Myositis Center in 2007, where he continues to see myositis patients as an adjunct faculty member. Dr. Mammen and his colleagues at Hopkins discovered a novel form of autoimmune myopathy associated with statin use and autoantibodies recognizing HMG-CoA reductase, the pharmacologic target of statins. In addition to clinical studies involving myositis patients, his current laboratory research interests include defining pathogenic mechanisms in the various forms of autoimmune myopathy and understanding the role of myositis autoantigens in muscle regeneration.

Scientific Publications

The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy.

Chung T, Christopher-Stine L, Paik JJ, Corse A, Mammen AL
Muscle & nerve.
2015 Aug;
52(2).
doi: 10.1002/mus.24642
PMID: 25737145

Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases.

Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, Tiniakou E, Petri M, Baer A, Danoff SK, Pak K, Casciola-Rosen LA, Mammen AL
Arthritis care & research.
2016 Jan;
68(1).
doi: 10.1002/acr.22600
PMID: 25892010

The Prevalence of Individual Histopathologic Features Varies according to Autoantibody Status in Muscle Biopsies from Patients with Dermatomyositis.

Pinal-Fernandez I, Casciola-Rosen LA, Christopher-Stine L, Corse AM, Mammen AL
The Journal of rheumatology.
2015 Aug;
42(8).
Last Updated: June 2020